Portal de Periódicos da CAPES

Targeting Chromatin in Fungal Pathogens as A Novel Therapeutic Strategy: Histone Modification Gets Infectious

2011; Future Medicine; Volume: 3; Issue: 2 Linguagem: Inglês

10.2217/epi.11.7

1750-1911

Denes Hnisz, Michael Tscherner, Karl Kuchler,

Plant-Microbe Interactions and Immunity

EpigenomicsVol. 3, No. 2 EditorialTargeting chromatin in fungal pathogens as a novel therapeutic strategy: histone modification gets infectiousDenes Hnisz, Michael Tscherner, Karl KuchlerDenes HniszMedical University Vienna, Christian Doppler Laboratory for Infection Biology, Max F Perutz Laboratories, A-1030 Vienna, Austria, Michael TschernerMedical University Vienna, Christian Doppler Laboratory for Infection Biology, Max F Perutz Laboratories, A-1030 Vienna, Austria, Karl Kuchler† Author for correspondenceMedical University Vienna, Christian Doppler Laboratory for Infection Biology, Max F Perutz Laboratories, A-1030 Vienna, Austria. Published Online:20 Apr 2011https://doi.org/10.2217/epi.11.7AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: antifungal drug discoverychromatin modificationepigeneticsfungal pathogensimmune evasionpathogenesisBibliography1 Kouzarides T: Chromatin modifications and their function. Cell128(4),693–705 (2007).Crossref, Medline, CAS, Google Scholar2 Jenuwein T, Allis CD: Translating the histone code. Science293(5532),1074–1080 (2001).Crossref, Medline, CAS, Google Scholar3 Smith E, Shilatifard A: The chromatin signaling pathway: diverse mechanisms of recruitment of histone-modifying enzymes and varied biological outcomes. Mol. Cell40(5),689–701 (2010).Crossref, Medline, CAS, Google Scholar4 Lopez-Rubio JJ, Riviere L, Scherf A: Shared epigenetic mechanisms control virulence factors in protozoan parasites. Curr. Opin. Microbiol.10(6),560–568 (2007).Crossref, Medline, CAS, Google Scholar5 Agbor-Enoh S, Seudieu C, Davidson E, Dritschilo A, Jung M: Novel inhibitor of Plasmodium histone deacetylase that cures P. berghei-infected mice. Antimicrob. Agents Chemother.53(5),1727–1734 (2009).Crossref, Medline, CAS, Google Scholar6 Van De Veerdonk FL, Kullberg BJ, Netea MG: Pathogenesis of invasive candidiasis. Curr. Opin. Crit. Care16(5),453–459 (2010).Crossref, Medline, Google Scholar7 Pfaller MA, Diekema DJ: Epidemiology of invasive candidiasis: a persistent public health problem. Clin. Microbiol. Rev.20(1),133–163 (2007).Crossref, Medline, CAS, Google Scholar8 Cowen LE: The evolution of fungal drug resistance: modulating the trajectory from genotype to phenotype. Nat. Rev. Microbiol.6(3),187–198 (2008).Crossref, Medline, CAS, Google Scholar9 Ferwerda G, Netea MG, Joosten LA, Van Der Meer JW, Romani L, Kullberg BJ: The role of Toll-like receptors and C-type lectins for vaccination against Candida albicans. Vaccine28(3),614–622 (2010).Crossref, Medline, CAS, Google Scholar10 Simonetti G, Passariello C, Rotili D, Mai A, Garaci E, Palamara AT: Histone deacetylase inhibitors may reduce pathogenicity and virulence in Candida albicans. FEMS Yeast Res.7(8),1371–1380 (2007).Crossref, Medline, CAS, Google Scholar11 Smith WL, Edlind TD: Histone deacetylase inhibitors enhance Candida albicans sensitivity to azoles and related antifungals: correlation with reduction in CDR and ERG upregulation. Antimicrob. Agents Chemother.46(11),3532–3539 (2002).Crossref, Medline, CAS, Google Scholar12 Pfaller MA, Messer SA, Georgopapadakou N, Martell LA, Besterman JM, Diekema DJ: Activity of MGCD290, a Hos2 histone deacetylase inhibitor, in combination with azole antifungals against opportunistic fungal pathogens. J. Clin. Microbiol.47(12),3797–3804 (2009).Crossref, Medline, CAS, Google Scholar13 Hnisz D, Majer O, Frohner IE, Komnenovic V, Kuchler K: The Set3/Hos2 histone deacetylase complex attenuates cAMP/PKA signaling to regulate morphogenesis and virulence of Candida albicans. PLoS Pathog.6(5),e1000889 (2010).Crossref, Medline, Google Scholar14 Lopes Da Rosa J, Boyartchuk VL, Zhu LJ, Kaufman PD: Histone acetyltransferase Rtt109 is required for Candida albicans pathogenesis. Proc. Natl Acad. Sci. USA107(4),1594–1599 (2009).Crossref, Google Scholar15 Wurtele H, Tsao S, Lepine G et al.: Modulation of histone H3 lysine 56 acetylation as an antifungal therapeutic strategy. Nat. Med.16(7),774–780 (2010).Crossref, Medline, CAS, Google Scholar16 Kottom TJ, Han J, Zhang Z, Limper AH: Pneumocystis carinii expresses an active Rtt109 histone acetyltransferase. Am. J. Respir. Cell Mol. Biol. doi:10.1165/rcmb.2009–0443OC (2010) (Epub ahead of print).Google Scholar17 Hnisz D, Schwarzmüller T, Kuchler K: Transcriptional loops meet chromatin: a dual-layer network controls white-opaque switching in Candida albicans. Mol. Microbiol.74(1),1–15 (2009).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetailsCited ByHistone Acetylation Regulator Gcn5 Mediates Drug Resistance and Virulence of Candida glabrataMicrobiology Spectrum, Vol. 10, No. 3Mechanisms to reduce the cytotoxicity of pharmacological nicotinamide concentrations in the pathogenic fungus Candida albicans28 December 2020 | The FEBS Journal, Vol. 288, No. 11The fungal‐specific histone acetyltransferase Rtt109 regulates development, DNA damage response, and virulence in Aspergillus fumigatus28 December 2020 | Molecular Microbiology, Vol. 115, No. 6Bre1 and Ubp8 regulate H2B mono‐ubiquitination and the reversible yeast‐hyphae transition in Candida albicans16 October 2020 | Molecular Microbiology, Vol. 115, No. 2Chromatin Structure and Drug Resistance in Candida spp.30 July 2020 | Journal of Fungi, Vol. 6, No. 3The Fungal Histone Acetyl Transferase Gcn5 Controls Virulence of the Human Pathogen Candida albicans through Multiple Pathways1 July 2019 | Scientific Reports, Vol. 9, No. 1Selective BET bromodomain inhibition as an antifungal therapeutic strategy18 May 2017 | Nature Communications, Vol. 8, No. 1Fungal KATs/KDACs: A New Highway to Better Antifungal Drugs?10 November 2016 | PLOS Pathogens, Vol. 12, No. 11Networks of genes modulating the pleiotropic drug response in Saccharomyces cerevisiae1 January 2014 | Mol. BioSyst., Vol. 10, No. 13 Systems Biology Approaches to Understanding and Predicting Fungal Virulence28 October 2013 Vol. 3, No. 2 Follow us on social media for the latest updates Metrics Downloaded 260 times History Published online 20 April 2011 Published in print April 2011 Information© Future Medicine LtdKeywordsantifungal drug discoverychromatin modificationepigeneticsfungal pathogensimmune evasionpathogenesisAcknowledgementsThe authors would like to apologize to colleagues who have contributed to this emerging field, yet whose work they were unable to cite owing to space constraints.Financial & competing interests disclosureWork in the authors' laboratory has been funded by grants from the Christian Doppler Research Society by the Austrian Science Foundations (FWF and FFG), and in part by the Vienna Biocenter PhD Program WK001 (to Denes Hnisz, and Michael Tscherner). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.PDF download